Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor
- PMID:9531525
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor
Abstract
K02 (morpholine-urea-Phe-Hphe-vinylsulfone), a newly developed peptidomimetic, acts as a potent cysteine protease inhibitor, especially of cathepsins B and L (which are associated with cancer progression) and cruzain (a cysteine protease of Trypanosoma cruzi, which is responsible for Chagas' disease). Here we investigated features of the disposition of K02 using in vitro systems, characterizing the interaction of the drug with human cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), a mediator of multidrug resistance (MDR) to cancer chemotherapy and a countertransporter in the intestine that limits oral drug bioavailability. P-gp functions as an ATP-dependent drug efflux pump to reduce intracellular cytotoxic concentrations. An HPLC assay was developed to analyze K02 and its metabolites formed in human liver microsomes. Three major primary metabolites were determined by LC/MS/MS to be hydroxylated products of the parent compound. A rabbit anti-CYP3A polyclonal antibody (200 microl antibody/mg microsomal protein) produced 75-94% inhibition of the formation of these three hydroxylated metabolites. Ketoconazole (5 microM), a selective CYP3A inhibitor, produced up to 75% inhibition, whereas other CYP-specific inhibitors, i.e. quinidine (CYP2D6), 7,8-benzoflavone (CYP1A2), and sulfaphenazole (CYP2C9), showed no significant effects. An identical metabolite formation profile for K02 was observed with cDNA-expressed human CYP3A4 (Gentest). These data demonstrate that K02 is a substrate for CYP3A. Formation of 1'-hydroxymidazolam, the primary human midazolam metabolite, was markedly inhibited by K02 via competitive processes, which suggests the potential for drug-drug interactions of K02 with other CYP3A substrates. K02 significantly inhibited the photoaffinity labeling of P-gp with azidopine and LU-49888, a photoaffinity analogue of verapamil. Transport studies with [14C]K02, using MDR1-transfected Madin-Darby canine kidney cell monolayers in the Transwell system, demonstrated that the basolateral-to-apical flux of K02 across MDR1-transfected Madin-Darby canine kidney cells was markedly greater than the apical-to-basolateral flux (ratio of 63 with 10 microM [14C]K02). This suggests that K02 is also a P-gp substrate. These studies are important for formulating strategies to increase the absorption and/or decrease the elimination of K02 and to optimize its delivery to malignant cells and parasite-infected host cells.
Similar articles
- Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.Zhang Y, Hsieh Y, Izumi T, Lin ET, Benet LZ.Zhang Y, et al.J Pharmacol Exp Ther. 1998 Oct;287(1):246-52.J Pharmacol Exp Ther. 1998.PMID:9765344
- Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.Wandel C, Kim RB, Guengerich FP, Wood AJ.Wandel C, et al.Drug Metab Dispos. 2000 Aug;28(8):895-8.Drug Metab Dispos. 2000.PMID:10901697
- Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M.Yumoto R, et al.Drug Metab Dispos. 2001 Feb;29(2):145-51.Drug Metab Dispos. 2001.PMID:11159804
- Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.Wacher VJ, Silverman JA, Zhang Y, Benet LZ.Wacher VJ, et al.J Pharm Sci. 1998 Nov;87(11):1322-30. doi: 10.1021/js980082d.J Pharm Sci. 1998.PMID:9811484Review.
- The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.Zhang Y, Benet LZ.Zhang Y, et al.Clin Pharmacokinet. 2001;40(3):159-68. doi: 10.2165/00003088-200140030-00002.Clin Pharmacokinet. 2001.PMID:11327196Review.
Cited by
- Drug transporters in pharmacokinetics.Petzinger E, Geyer J.Petzinger E, et al.Naunyn Schmiedebergs Arch Pharmacol. 2006 Mar;372(6):465-75. doi: 10.1007/s00210-006-0042-9. Epub 2006 Mar 11.Naunyn Schmiedebergs Arch Pharmacol. 2006.PMID:16532306Review.
- Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats.Li C, Kim CS, Yang JY, Park YJ, Choi JS.Li C, et al.Eur J Drug Metab Pharmacokinet. 2008 Oct-Dec;33(4):231-6. doi: 10.1007/BF03190877.Eur J Drug Metab Pharmacokinet. 2008.PMID:19230596
- Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.Ito K, Kusuhara H, Sugiyama Y.Ito K, et al.Pharm Res. 1999 Feb;16(2):225-31. doi: 10.1023/a:1018872207437.Pharm Res. 1999.PMID:10100307
- Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL.Polli JW, et al.Pharm Res. 1999 Aug;16(8):1206-12. doi: 10.1023/a:1018941328702.Pharm Res. 1999.PMID:10468021
- Vinyl sulfones as antiparasitic agents and a structural basis for drug design.Kerr ID, Lee JH, Farady CJ, Marion R, Rickert M, Sajid M, Pandey KC, Caffrey CR, Legac J, Hansell E, McKerrow JH, Craik CS, Rosenthal PJ, Brinen LS.Kerr ID, et al.J Biol Chem. 2009 Sep 18;284(38):25697-703. doi: 10.1074/jbc.M109.014340. Epub 2009 Jul 20.J Biol Chem. 2009.PMID:19620707Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Miscellaneous